These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1415022)

  • 1. Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-alpha therapy.
    Wu PC; Lok AS; Lau JY; Lauder IJ; Lai CL
    Am J Clin Pathol; 1992 Oct; 98(4):402-7. PubMed ID: 1415022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy.
    Ozer E; Ozer E; Helvaci M; Yaprak I
    Liver; 1999 Oct; 19(5):369-74. PubMed ID: 10533793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild-type and precore mutant hepatitis B virus infections.
    Bayraktar Y; Koseoglu T; Temizer A; Kayhan B; Van Thiel DH; Uzunalimoglu B
    J Viral Hepat; 1996 May; 3(3):137-42. PubMed ID: 8871872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA
    Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha therapy with and without interferon-alpha priming in patients with chronic hepatitis B infection.
    Catterall AP; King R; Lau JY; Daniels HM; Alexander GJ; Murray-Lyon IM; Williams R
    J Antimicrob Chemother; 1993 May; 31(5):777-82. PubMed ID: 8335505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon.
    Lisker-Melman M; Webb D; Di Bisceglie AM; Kassianides C; Martin P; Rustgi V; Waggoner JG; Park Y; Hoofnagle JH
    Ann Intern Med; 1989 Sep; 111(6):479-83. PubMed ID: 2774373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of hepatitis B virus DNA in hepatocytes of patients with noncarcinomatous liver disease. Its special relationship with necroinflammatory activity and the stage of disease.
    Tozuka S; Uchida T; Suzuki K; Esumi M; Shikata T
    Arch Pathol Lab Med; 1989 Jan; 113(1):20-5. PubMed ID: 2910223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A prospective study on histological and serological changes after interferon alpha-2b treatment in patients with chronic hepatitis B infection].
    Lang Z; Zhao C; Xu D
    Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):145-7. PubMed ID: 11517899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis B virus infection. Viral replication and patterns of inflammatory activity: serological, clinical and histological correlations.
    Paz MO; Brenes F; Karayiannis P; Jowett TP; Scheuer PJ; Thomas HC
    J Hepatol; 1986; 3(3):371-7. PubMed ID: 3549868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change of hepatitis B virus DNA distribution associated with the progression of chronic hepatitis.
    Michitaka K; Horiike N; Nadano S; Onji M; Ohta Y
    Liver; 1988 Aug; 8(4):247-53. PubMed ID: 3419292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.
    Hasegawa I; Orito E; Tanaka Y; Hirashima N; Sakakibara K; Sakurai M; Suzuki S; Sugauchi F; Ohno T; Ueda R; Mizokami M
    Liver Int; 2005 Apr; 25(2):247-53. PubMed ID: 15780046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
    Lampertico P; Del Ninno E; Manzin A; Donato MF; Rumi MG; Lunghi G; Morabito A; Clementi M; Colombo M
    Hepatology; 1997 Dec; 26(6):1621-5. PubMed ID: 9398007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection.
    Marinos G; Naoumov NV; Rossol S; Torre F; Wong PY; Gallati H; Portmann B; Williams R
    Gastroenterology; 1995 May; 108(5):1453-63. PubMed ID: 7729638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection.
    Marinos G; Naoumov NV; Williams R
    Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation.
    Protzer U; Goergen B; Hopf U; Neuhaus P; König V; Meyer zum Büschenfelde KH; Gerken G
    J Med Virol; 1996 Oct; 50(2):135-44. PubMed ID: 8915879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
    Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
    Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B-DNA replication and histological patterns in liver biopsy specimens of chronic HBsAg positive patients with and without hepatitis delta virus superinfection.
    Villari D; Raimondo G; Smedile V; Rodinó G; Brancatelli S; Longo G; Squadrito G; Batolo D
    J Clin Pathol; 1989 Jul; 42(7):689-93. PubMed ID: 2760230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment.
    Han HL; Lang ZW
    World J Gastroenterol; 2003 Jan; 9(1):117-21. PubMed ID: 12508364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.